The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The c-Met receptor tyrosine kinase pathway, activated by hepatocyte growth factor (HGF), is implicated in various human cancers, including hepatocellular carcinoma (HCC).
• Aberrant c-Met signaling contributes to tumor growth, invasion, and metastasis in HCC.
• Targeting the c-Met pathway presents a potential therapeutic strategy for HCC.

Purpose of the Study:

• To evaluate the in vivo antitumor and antimetastatic efficacy of the novel c-Met inhibitor MSC2156119J.
• To assess the drug's activity in patient-derived primary liver cancer explants.
• To compare the efficacy and tolerability of MSC2156119J with sorafenib, a standard HCC treatment.

Main Methods:

• In vivo studies using mice xenograft models with MHCC97H cells and patient-derived HCC explants.
• Administration of MSC2156119J (10, 30, 100 mg/kg) and sorafenib (50 mg/kg) as single agents or in combination.
• Monitoring of tumor growth, metastasis formation, and alpha fetoprotein (AFP) levels.

Main Results:

• MSC2156119J demonstrated significant inhibition of tumor growth and induced complete regression in HCC models.
• Treatment with MSC2156119J led to undetectable AFP levels and reduced lung metastasis.
• Patient-derived explants with high c-Met/HGF expression showed greater sensitivity to MSC2156119J, with comparable or superior efficacy to sorafenib.
• Tumors with low c-Met expression were less responsive.
• MSC2156119J was better tolerated than sorafenib, and combination therapy offered no additional benefit.

Conclusions:

• Selective inhibition of c-Met/HGF signaling with MSC2156119J exhibits potent antitumor and antimetastatic activity in HCC.
• MSC2156119J shows promise as a targeted therapy for HCC patients with active c-Met signaling.
• The drug's favorable tolerability profile further supports its clinical development for HCC treatment.